Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammopharmacology
Published in: Inflammopharmacology 5/2023

10-07-2023 | Review

Pyroptosis: the potential eye of the storm in adult-onset Still’s disease

Authors: Xinglan He, Ruixuan You, Yaqian Shi, Zhuotong Zeng, Bingsi Tang, Jiangfan Yu, Yangfan Xiao, Rong Xiao

Published in: Inflammopharmacology | Issue 5/2023

Login to get access

Abstract

Pyroptosis, a form of programmed cell death with a high pro-inflammatory effect, causes cell lysis and leads to the secretion of countless interleukin-1β (IL-1β) and IL-18 cytokines, resulting in a subsequent extreme inflammatory response through the caspase-1-dependent pathway or caspase-1-independent pathway. Adult-onset Still’s disease (AOSD) is a systemic inflammatory disease with extensive disease manifestations and severe complications such as macrophage activation syndrome, which is characterized by high-grade inflammation and cytokine storms regulated by IL-1β and IL-18. To date, the pathogenesis of AOSD is unclear, and the available therapy is unsatisfactory. As such, AOSD is still a challenging disease. In addition, the high inflammatory states and the increased expression of multiple pyroptosis markers in AOSD indicate that pyroptosis plays an important role in the pathogenesis of AOSD. Accordingly, this review summarizes the molecular mechanisms of pyroptosis and describes the potential role of pyroptosis in AOSD, the therapeutic practicalities of pyroptosis target drugs in AOSD, and the therapeutic blueprint of other pyroptosis target drugs.
Literature
Ahn MH, Han JH, Chwae YJ, Jung JY, Suh CH, Kwon JE, Kim HA (2019) Neutrophil extracellular traps may contribute to the pathogenesis in adult-onset still disease. J Rheumatol 46:1560–1569PubMedCrossRef
Akimova T, Zhang T, Christensen LM, Wang Z, Han R, Negorev D, Samanta A, Sasson IE, Gaddapara T, Jiao J, Wang L, Bhatti TR, Levine MH, Diamond JM, Beier UH, Simmons RA, Cantu E, Wilkes DS, Lederer DJ, Anderson M, Christie JD, Hancock WW (2021) Obesity-related IL-18 impairs T-regulatory cell function and promotes lung ischemia-reperfusion injury. Am J Respir Crit Care Med 204:1060–1074PubMedPubMedCentralCrossRef
Al Mamun A, Suchi SA, Aziz MA, Zaeem M, Munir F, Wu Y, Xiao J (2022) Pyroptosis in acute pancreatitis and its therapeutic regulation. Apoptosis 910:1744
Andersson U (2021) Hyperinflammation: on the pathogenesis and treatment of macrophage activation syndrome. Acta Paediatr 110:2717–2722PubMedCrossRef
Arlet JB, Le TH, Marinho A, Amoura Z, Wechsler B, Papo T, Piette JC (2006) Reactive haemophagocytic syndrome in adult-onset Still’s disease: a report of six patients and a review of the literature. Ann Rheum Dis 65:1596–1601PubMedPubMedCentralCrossRef
Audia JP, Yang XM, Crockett ES, Housley N, Haq EU, O’Donnell K, Cohen MV, Downey JM, Alvarez DF (2018) Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y(12) receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function. Basic Res Cardiol 113:32PubMedPubMedCentralCrossRef
Banse C, Vittecoq O, Benhamou Y, Gauthier-Prieur M, Lequerre T, lévesque H (2013) Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still’s disease. Joint Bone Spine 80:653–655PubMedCrossRef
Barsotti S, Neri R, Iacopetti V, D’Ascanio A, Talarico R, Tripoli A, Bombardieri S (2014) Successful treatment of refractory adult-onset still disease with canakinumab: a case report. J Clin Rheumatol 20:121PubMedCrossRef
Bent R, Moll L, Grabbe S, Bros M (2018) Interleukin-1 beta-a friend or foe in malignancies? Int J Mol Sci 19:223CrossRef
Busch K, Kny M, Huang N, Klassert TE, Stock M, Hahn A, Graeger S, Todiras M, Schmidt S, Chamling B, Willenbrock M, Groß S, Biedenweg D, Heuser A, Scheidereit C, Butter C, Felix SB, Otto O, Luft FC, Slevogt H, Fielitz J (2021) Inhibition of the NLRP3/IL-1β axis protects against sepsis-induced cardiomyopathy. J Cachexia Sarcopenia Muscle 12:1653–1668PubMedPubMedCentralCrossRef
Canna SW, de Jesus AA, Gouni S, Brooks SR, Marrero B, Liu Y, Dimattia MA, Zaal KJ, Sanchez GA, Kim H, Chapelle D, Plass N, Huang Y, Villarino AV, Biancotto A, Fleisher TA, Duncan JA, O’Shea JJ, Benseler S, Grom A, Deng Z, Laxer RM, Goldbach-Mansky R (2014) An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet 46:1140–1146PubMedPubMedCentralCrossRef
Carty M, Kearney J, Shanahan KA, Hams E, Sugisawa R, Connolly D, Doran CG, Muñoz-Wolf N, Gürtler C, Fitzgerald KA, Lavelle EC, Fallon PG, Bowie AG (2019) Cell survival and cytokine release after inflammasome activation is regulated by the Toll-IL-1R protein SARM. Immunity 50:1412-1424.e6PubMedCrossRef
Chen DY, Lan JL, Lin FJ, Hsieh TY (2004a) Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still’s disease. J Rheumatol 31:2189–2198PubMed
Chen DY, Lan JL, Lin FJ, Hsieh TY, Wen MC (2004b) Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still’s disease. Ann Rheum Dis 63:1300–1306PubMedPubMedCentralCrossRef
Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL (2010a) The associations of circulating CD4+CD25high regulatory T cells and TGF-β with disease activity and clinical course in patients with adult-onset Still’s disease. Conn Tissue Res 51:370–377CrossRef
Chen DY, Chen YM, Lan JL, Lin CC, Chen HH, Hsieh CW (2010b) Potential role of Th17 cells in the pathogenesis of adult-onset Still’s disease. Rheumatology (oxford) 49:2305–2312PubMedCrossRef
Chen DY, Lin CC, Chen YM, Lan JL, Hung WT, Chen HH, Lai KL, Hsieh CW (2013) Involvement of TLR7 MyD88-dependent signaling pathway in the pathogenesis of adult-onset Still’s disease. Arthritis Res Ther 15:R39PubMedPubMedCentralCrossRef
Chen X, He WT, Hu L, Li J, Fang Y, Wang X, Xu X, Wang Z, Huang K, Han J (2016) Pyroptosis is driven by non-selective gasdermin-D pore and its morphology is different from MLKL channel-mediated necroptosis. Cell Res 26:1007–1020PubMedPubMedCentralCrossRef
Chen DY, Chen YM, Chen HH, Hsieh CW, Gung NR, Hung WT, Tzang BS, Hsu TC (2018a) Human parvovirus B19 nonstructural protein NS1 activates NLRP3 inflammasome signaling in adult-onset Still’s disease. Mol Med Rep 17:3364–3371PubMed
Chen KW, Monteleone M, Boucher D, Sollberger G, Ramnath D, Condon ND, von Pein JB, Broz P, Sweet MJ, Schroder K (2018b) Noncanonical inflammasome signaling elicits gasdermin D-dependent neutrophil extracellular traps. Sci Immunol 3:334CrossRef
Chen L, Zhao Y, Lai D, Zhang P, Yang Y, Li Y, Fei K, Jiang G, Fan J (2018c) Neutrophil extracellular traps promote macrophage pyroptosis in sepsis. Cell Death Dis 9:597PubMedPubMedCentralCrossRef
Cho KA, Suh JW, Lee KH, Kang JL, Woo SY (2012) IL-17 and IL-22 enhance skin inflammation by stimulating the secretion of IL-1β by keratinocytes via the ROS-NLRP3-caspase-1 pathway. Int Immunol 24:147–158PubMedCrossRef
Choi JH, Suh CH, Lee YM, Suh YJ, Lee SK, Kim SS, Nahm DH, Park HS (2003) Serum cytokine profiles in patients with adult onset Still’s disease. J Rheumatol 30:2422–2427PubMed
Cipriani P, Ruscitti P, Carubbi F, Pantano I, Liakouli V, Berardicurti O, Giacomelli R (2014) Tocilizumab for the treatment of adult-onset Still’s disease: results from a case series. Clin Rheumatol 33:49–55PubMedCrossRef
Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang DL, Crooks DR, Sougrat R, Morgenstern A, Galy B, Hentze MW, Lazaro FJ, Rouault TA, Meyron-Holtz EG (2010) Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood 116:1574–1584PubMedCrossRef
Colafrancesco S, Priori R, Valesini G, Argolini L, Baldissera E, Bartoloni E, Cammelli D, Canestrari G, Cantarini L, Cavallaro E, Cavalli G, Cerrito L, Cipriani P, Dagna L, Marchi G, Vita S, Emmi G, Ferraccioli G, Frassi M, Galeazzi M, Gerli R, Giacomelli R, Gremese E, Iannone F, Lapadula G, Lopalco G, Manna R, Mathieu A, Montecucco C, Mosca M, Piazza I, Piga M, Pontikaki I, Romano M, Rossi S, Rossini M, Ruscitti P, Silvestri E, Stagnaro C, Talarico R, Tincani A, Viapiana O, Vitiello G, Fabris F, Bindoli S, Punzi L, Galozzi P, Sfriso P (2017) Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still’s Disease: A Multicentre Retrospective Observational Study. Front Pharmacol 8:369PubMedPubMedCentralCrossRef
Colafrancesco S, Alessandri C, Conti F, Priori R (2020) COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome? Autoimmun Rev 19:102573PubMedPubMedCentralCrossRef
Coutermarsh-Ott S, Eden K, Allen IC (2016) Beyond the inflammasome: regulatory NOD-like receptor modulation of the host immune response following virus exposure. J Gen Virol 97:825–838PubMedPubMedCentralCrossRef
Daibata M, Taguchi H (2002) Human herpesvirus 6 and adult-onset Still’s disease. Am J Med 113:532PubMedCrossRef
de Clerck KF, van Offel JF, Vlieghe E, van Marck E, Stevens WJ (2008) Bartonella endocarditis mimicking adult Still’s disease. Acta Clin Belg 63:190–192PubMedCrossRef
el Mezayen R, el Gazzar M, Seeds MC, McCall CE, Dreskin SC, Nicolls MR (2007) Endogenous signals released from necrotic cells augment inflammatory responses to bacterial endotoxin. Immunol Lett 111:36–44PubMedPubMedCentralCrossRef
Elkayam O, Jiries N, Dranitzki Z, Kivity S, Lidar M, Levy O, Ablin J, Abu-Shakra M, Savargyl-Maman H, Padova H, Caspi D, Rosner I (2014) Tocilizumab in adult-onset Still’s disease: the Israeli experience. J Rheumatol 41:244–247PubMedCrossRef
Fan W, Chen S, Wu X, Zhu J, Li J (2021) Resveratrol Relieves gouty arthritis by promoting mitophagy to inhibit activation of NLRP3 inflammasomes. J Inflamm Res 14:3523–3536PubMedPubMedCentralCrossRef
Fang Y, Tian S, Pan Y, Li W, Wang Q, Tang Y, Yu T, Wu X, Shi Y, Ma P, Shu Y (2020) Pyroptosis: a new frontier in cancer. Biomed Pharmacother 121:109595PubMedCrossRef
Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES (2009) AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 458:509–513PubMedPubMedCentralCrossRef
Fillmore N, Bell S, Shen C, Nguyen V, La J, Dubreuil M, Strymish J, Brophy M, Mehta G, Wu H, Lieberman J, Do N, Sander C (2021) Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study. PLoS ONE 16:e0259061PubMedPubMedCentralCrossRef
Flisiak-Jackiewicz M, Bobrus-Chociej A, Tarasów E, Wojtkowska M, Białokoz-Kalinowska I, Lebensztejn DM (2018) Predictive role of interleukin-18 in liver steatosis in obese Children. Can J Gastroenterol Hepatol 2018:3870454PubMedPubMedCentral
Friedlander AM (1986) Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J Biol Chem 261:7123–7126PubMedCrossRef
Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA, Martin T, Hellmich B, Lamprecht P, Schulze-Koops H, Courvoisier DS, Sleight A, Schiffrin EJ (2018) Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease. Ann Rheum Dis 77:840–847PubMed
Gao Q, Yuan Y, Wang Y, Jiang J, Ye Z, Liu T, Jiang Z, Zhao L (2021) Clinical characteristics of macrophage activation syndrome in adult-onset Still’s disease. Clin Exp Rheumatol 39(132):59–66PubMedCrossRef
Gaul S, Leszczynska A, Alegre F, Kaufmann B, Johnson CD, Adams LA, Wree A, Damm G, Seehofer D, Calvente CJ, Povero D, Kisseleva T, Eguchi A, McGeough MD, Hoffman HM, Pelegrin P, Laufs U, Feldstein AE (2021) Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis. J Hepatol 74:156–167PubMedCrossRef
Ge G, Bai J, Wang Q, Liang X, Tao H, Chen H, Wei M, Niu J, Yang H, Xu Y, Hao Y, Xue Y, Geng D (2022) Punicalagin ameliorates collagen-induced arthritis by downregulating M1 macrophage and pyroptosis via NF-κB signaling pathway. Sci China Life Sci 65:588–603PubMedCrossRef
Gerfaud-Valentin M, Jamilloux Y, Iwaz J, SèVE P (2014) Adult-onset Still’s disease. Autoimmun Rev 13:708–722PubMedCrossRef
Giacomelli R, Ruscitti P, Shoenfeld Y (2018) A comprehensive review on adult onset Still’s disease. J Autoimmun 93:24–36PubMedCrossRef
Giampietro C, Ridene M, Lequerre T, Costedoat Chalumeau N, Amoura Z, Sellam J, Sibilia J, Bourgeois P, Fautrel B (2013) Anakinra in adult-onset Still’s disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res (hoboken) 65:822–826PubMedCrossRef
Gomez A, Serrano A, Salero E, Tovar A, Amescua G, Galor A, Keane RW, De Rivero Vaccari JP, Sabater AL (2021) Tumor necrosis factor-alpha and interferon-gamma induce inflammasome-mediated corneal endothelial cell death. Exp Eye Res 207:108574PubMedCrossRef
Guo W, Chen S, Li C, Xu J, Wang L (2021) Application of disulfiram and its metabolites in treatment of inflammatory disorders. Front Pharmacol 12:795078PubMedCrossRef
Han JH, Suh CH, Jung JY, Ahn MH, Kwon JE, Yim H, Kim HA (2017) Serum levels of interleukin 33 and soluble ST2 are associated with the extent of disease activity and cutaneous manifestations in patients with active adult-onset still’s disease. J Rheumatol 44:740–747PubMedCrossRef
Hasanzadeh S, Read MI, Bland AR, Majeed M, Jamialahmadi T, Sahebkar A (2020) Curcumin: an inflammasome silencer. Pharmacol Res 159:104921PubMedCrossRef
Hou J, Zhao R, Xia W, Chang CW, You Y, Hsu JM, Nie L, Chen Y, Wang YC, Liu C, Wang WJ, Wu Y, Ke B, Hsu JL, Huang K, Ye Z, Yang Y, Xia X, Li Y, Li CW, Shao B, Tainer JA, Hung MC (2020) PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat Cell Biol 22:1264–1275PubMedPubMedCentralCrossRef
Hu Q, Shi H, Zeng T, Liu H, Su Y, Cheng X, Ye J, Yin Y, Liu M, Zheng H, Wu X, Chi H, Zhou Z, Jia J, Sun Y, Teng J, Yang C (2019) Increased neutrophil extracellular traps activate NLRP3 and inflammatory macrophages in adult-onset Still’s disease. Arthritis Res Ther 21:9PubMedPubMedCentralCrossRef
Hu JJ, Liu X, Xia S, Zhang Z, Zhang Y, Zhao J, Ruan J, Luo X, Lou X, Bai Y, Wang J, Hollingsworth LR, Magupalli VG, Zhao L, Luo HR, Kim J, Lieberman J, Wu H (2020) FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nat Immunol 21:736–745PubMedPubMedCentralCrossRef
Inoue N, Shimizu M, Tsunoda S, Kawano M, Matsumura M, Yachie A (2016) Cytokine profile in adult-onset Still’s disease: Comparison with systemic juvenile idiopathic arthritis. Clin Immunol 169:8–13PubMedCrossRef
Jamilloux Y, Gerfaud-Valentin M, Martinon F, Belot A, Henry T, SèVE P (2015) Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart. Immunol Res 61:53–62PubMedCrossRef
Jia J, Wang M, Ma Y, Teng J, Shi H, Liu H, Sun Y, Su Y, Meng J, Chi H, Chen X, Cheng X, Ye J, Liu T, Wang Z, Wan L, Zhou Z, Wang F, Yang C, Hu Q (2020) Circulating neutrophil extracellular traps signature for identifying organ involvement and response to glucocorticoid in adult-onset still’s disease: a machine learning study. Front Immunol 11:563335PubMedPubMedCentralCrossRef
Jiao Y, Zhang T, Zhang C, Ji H, Tong X, Xia R, Wang W, Ma Z, Shi X (2021) Exosomal miR-30d-5p of neutrophils induces M1 macrophage polarization and primes macrophage pyroptosis in sepsis-related acute lung injury. Crit Care 25:356PubMedPubMedCentralCrossRef
Jolly L, Carrasco K, Salcedo-Magguilli M, Garaud JJ, Lambden S, van der Poll T, Mebazaa A, Laterre PF, Gibot S, Boufenzer A, Derive M (2021) sTREM-1 is a specific biomarker of TREM-1 pathway activation. Cell Mol Immunol 18:2054–2056PubMedPubMedCentralCrossRef
Jung JY, Suh CH, Sohn S, Nam JY, Kim HA (2016) Elevated high-mobility group B1 levels in active adult-onset Still’s disease associated with systemic score and skin rash. Clin Rheumatol 35:1937–1942PubMedCrossRef
Junge G, Mason J, Feist E (2017) Adult onset Still’s disease-The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review). Semin Arthritis Rheum 47:295–302PubMedCrossRef
Kang R, Zeng L, Zhu S, Xie Y, Liu J, Wen Q, Cao L, Xie M, Ran Q, Kroemer G, Wang H, Billiar TR, Jiang J, Tang D (2018) Lipid peroxidation drives gasdermin D-mediated pyroptosis in lethal polymicrobial sepsis. Cell Host Microbe 24:97-108.e4PubMedPubMedCentralCrossRef
Kany S, Vollrath JT, Relja B (2019) Cytokines in inflammatory disease. Int J Mol Sci 20:223CrossRef
Karki R, Sharma BR, Tuladhar S, Williams EP, Zalduondo L, Samir P, Zheng M, Sundaram B, Banoth B, Malireddi RKS, Schreiner P, Neale G, Vogel P, Webby R, Jonsson CB, Kanneganti TD (2021) Synergism of TNF-α and IFN-γ Triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell 184:149-168.e17PubMedCrossRef
Karmakar M, Minns M, Greenberg EN, Diaz-Aponte J, Pestonjamasp K, Johnson JL, Rathkey JK, Abbott DW, Wang K, Shao F, Catz SD, Dubyak GR, Pearlman E (2020) N-GSDMD trafficking to neutrophil organelles facilitates IL-1β release independently of plasma membrane pores and pyroptosis. Nat Commun 11:2212PubMedPubMedCentralCrossRef
Kelley N, Jeltema D, Duan Y, He Y (2019) The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. Int J Mol Sci 20:4453CrossRef
Kiltz U, Kiefer D, Braun J, Schiffrin EJ, Girard-Guyonvarc’h C, Gabay C (2020) Prolonged treatment with tadekinig alfa in adult-onset still’s disease. Ann Rheum Dis 79:e10PubMedCrossRef
Kim HA, Han JH, Kim WJ, Noh HJ, An JM, Yim H, Jung JY, Kim YS, Suh CH (2016) TLR4 endogenous ligand S100A8/A9 levels in adult-onset still’s disease and their association with disease activity and clinical manifestations. Int J Mol Sci 17:1342PubMedPubMedCentralCrossRef
Kim HA, Choi B, Suh CH, Han MH, Jung JY, Sayeed HM, Kim YW, Sohn S (2017) Highly expression of CD11b and CD32 on peripheral blood mononuclear cells from patients with adult-onset still’s disease. Int J Mol Sci 18:445
Koch CA, Krabbe S, Hehmke B (2018) Statins, metformin, proprotein-convertase-subtilisin-kexin type-9 (PCSK9) inhibitors and sex hormones: Immunomodulatory properties? Rev Endocr Metab Disord 19:363–395PubMedCrossRef
Komiya A, Matsui T, Nogi S, Iwata K, Futami H, Takaoka H, Arinuma Y, Hashimoto A, Shimada K, Ikenaka T, Nakayama H, Furukawa H, Tohma S (2012) Neutrophil CD64 is upregulated in patients with active adult-onset Still’s disease. Scand J Rheumatol 41:156–158PubMedCrossRef
Kontzias A, Efthimiou P (2012) The use of Canakinumab, a novel IL-1β long-acting inhibitor, in refractory adult-onset Still’s disease. Semin Arthritis Rheum 42:201–205PubMedCrossRef
Kroemer A, Khan K, Plassmeyer M, Alpan O, Haseeb MA, Gupta R, Fishbein TM (2020) Inflammasome activation and pyroptosis in lymphopenic liver patients with COVID-19. J Hepatol 73:1258–1262PubMedPubMedCentralCrossRef
Lagrange B, Benaoudia S, Wallet P, Magnotti F, Provost A, Michal F, Martin A, di Lorenzo F, Py BF, Molinaro A, Henry T (2018) Human caspase-4 detects tetra-acylated LPS and cytosolic Francisella and functions differently from murine caspase-11. Nat Commun 9:242PubMedPubMedCentralCrossRef
Lee BL, Stowe IB, Gupta A, Kornfeld OS, Roose-Girma M, Anderson K, Warming S, Zhang J, Lee WP, Kayagaki N (2018) Caspase-11 auto-proteolysis is crucial for noncanonical inflammasome activation. J Exp Med 215:2279–2288PubMedPubMedCentralCrossRef
Li H, Li Y, Song C, Hu Y, Dai M, Liu B, Pan P (2021) Neutrophil Extracellular Traps Augmented Alveolar Macrophage Pyroptosis via AIM2 Inflammasome Activation in LPS-Induced ALI/ARDS. J Inflamm Res 14:4839–4858PubMedPubMedCentralCrossRef
Liu F, Liu T, Sun M, Zhou J, Xue F, Chen S, Chen J, Zhang L (2021) Maxing Shigan Decoction Mitigates Mycoplasma pneumonia-Induced Pyroptosis in A549 Cells via the NLRP3 Inflammasome. Infect Drug Resist 14:859–867PubMedPubMedCentralCrossRef
Liu X, Lin Z, Yin X (2022) Pellino2 accelerate inflammation and pyroptosis via the ubiquitination and activation of NLRP3 inflammation in model of pediatric pneumonia. Int Immunopharmacol 110:108993PubMedCrossRef
Lo Gullo A, Caruso A, Pipitone N, Macchioni P, Pazzola G, Salvarani C (2014) Canakinumab in a case of adult onset still’s disease: efficacy only on systemic manifestations. Joint Bone Spine 81:376–377PubMedCrossRef
Locati M, Curtale G, Mantovani A (2020) Diversity, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol 15:123–147PubMedCrossRef
Lopez-Rodriguez AB, Hennessy E, Murray CL, Nazmi A, Delaney HJ, Healy D, Fagan SG, Rooney M, Stewart E, Lewis A, de Barra N, Scarry P, Riggs-Miller L, Boche D, Cunningham MO, Cunningham C (2021) Acute systemic inflammation exacerbates neuroinflammation in Alzheimer’s disease: IL-1β drives amplified responses in primed astrocytes and neuronal network dysfunction. Alzheimers Dement 17:1735–1755PubMedPubMedCentralCrossRef
Mailer RK, Joly AL, Liu S, Elias S, Tegner J, Andersson J (2015) IL-1β promotes Th17 differentiation by inducing alternative splicing of FOXP3. Sci Rep 5:14674PubMedPubMedCentralCrossRef
Maranini B, Ciancio G, Govoni M (2021) Adult-onset still’s disease: novel biomarkers of specific subsets, disease activity, and relapsing forms. Int J Mol Sci 22:13320PubMedPubMedCentralCrossRef
Martynova E, Rizvanov A, Urbanowicz RA, Khaiboullina S (2022) Inflammasome Contribution to the Activation of Th1, Th2, and Th17 Immune Responses. Front Microbiol 13:851835PubMedPubMedCentralCrossRef
Mathur A, Hayward JA, Man SM (2018) Molecular mechanisms of inflammasome signaling. J Leukoc Biol 103:233–257PubMedCrossRef
Myachikova V, Moiseeva O, Konradi A, Lapin SV, Tkachenko O, Nazarov V, Feist E, Maslyanskiy A (2022) A retrospective analysis of colchicine in combination with NSAIDs therapy in patients with systemic form of adult-onset Still’s disease with serositis. Clin Exp Rheumatol 40:1474–1479PubMed
Nagai H, Kirino Y, Nakano H, Kunishita Y, Henmi R, Szymanski AM, Yoshimi R, Ombrello MJ, Nakajima H (2021) Elevated serum gasdermin D N-terminal implicates monocyte and macrophage pyroptosis in adult-onset Still’s disease. Rheumatology (oxford) 60:3888–3895PubMedCrossRef
Nagareddy PR, Kraakman M, Masters SL, Stirzaker RA, Gorman DJ, Grant RW, Dragoljevic D, Hong ES, Abdel-Latif A, Smyth SS, Choi SH, Korner J, Bornfeldt KE, Fisher EA, Dixit VD, Tall AR, Goldberg IJ, Murphy AJ (2014) Adipose tissue macrophages promote myelopoiesis and monocytosis in obesity. Cell Metab 19:821–835PubMedPubMedCentralCrossRef
Nerurkar L, Siebert S, McInnes IB, Cavanagh J (2019) Rheumatoid arthritis and depression: an inflammatory perspective. Lancet Psychiatry 6:164–173PubMedCrossRef
Nirmala N, Brachat A, Feist E, Blank N, Specker C, Witt M, Zernicke J, Martini A, Junge G (2015) Gene-expression analysis of adult-onset Still’s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol Online J 13:50PubMedPubMedCentralCrossRef
Nordström D, Knight A, Luukkainen R, Van Vollenhoven R, Rantalaiho V, Kajalainen A, Brun JG, Proven A, Ljung L, Kautiainen H, Pettersson T (2012) Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still’s disease. An open, randomized, multicenter study. J Rheumatol 39:2008–2011PubMedCrossRef
Parisien M, Lima LV, Dagostino C, El-Hachem N, Drury GL, Grant AV, Huising J, Verma V, Meloto CB, Silva JR, Dutra GGS, Markova T, Dang H, Tessier PA, Slade GD, Nackley AG, Ghasemlou N, Mogil JS, Allegri M, Diatchenko L (2022) Acute inflammatory response via neutrophil activation protects against the development of chronic pain. Sci Transl Med 14:9954CrossRef
Park SH, Ham S, Lee A, MöLLER A (2019) NLRP3 negatively regulates Treg differentiation through Kpna2-mediated nuclear translocation. J Biol Chem 294:17951–17961PubMedPubMedCentralCrossRef
Perez C, Artola V (2001) Adult Still’s disease associated with Mycoplasma pneumoniae infection. Clin Infect Dis 32:E105–E106PubMedCrossRef
Petagna L, Antonelli A, Ganini C, Bellato V, Campanelli M, Divizia A, Efrati C, Franceschilli M, Guida AM, Ingallinella S, Montagnese F, Sensi B, Siragusa L, Sica GS (2020) Pathophysiology of Crohn’s disease inflammation and recurrence. Biol Direct 15:23PubMedPubMedCentralCrossRef
Petryna O, Cush JJ, Efthimiou P (2012) IL-1 Trap rilonacept in refractory adult onset Still’s disease. Ann Rheum Dis 71:2056–2057PubMedCrossRef
Puéchal X, Debandt M, Berthelot JM, Breban M, Dubost JJ, Fain O, Kahn JE, Lequen L, Longy-Boursier M, Perdriger A, Schaeverbeke T, Toussirot E, Sibilia J (2011) Tocilizumab in refractory adult Still’s disease. Arthritis Care Res (hoboken) 63:155–159PubMedCrossRef
Rao S, Li Q, Wu H, Zhao M, Wang A, Zhang G, Li J, Lu L, Shi W, Lu Q (2019) Juxtaposition of IL-1β and IFN-γ expression and apoptosis of keratinocytes in adult-onset Still’s disease. Expert Rev Clin Immunol 15:1341–1350PubMedCrossRef
Rex DAB, Keshava Prasad TS, Kandasamy RK (2022) Revisiting Regulated Cell Death Responses in Viral Infections. Int J Mol Sci 23:443CrossRef
Richter J, Brouwer S, Schroder K, Walker MJ (2021) Inflammasome activation and IL-1β signalling in group a streptococcus disease. Cell Microbiol 23:e13373PubMedCrossRef
Robinson N, Ganesan R, Hegedűs C, Kovács K, Kufer TA, Virág L (2019) Programmed necrotic cell death of macrophages: focus on pyroptosis, necroptosis, and parthanatos. Redox Biol 26:101239PubMedPubMedCentralCrossRef
Sarhan J, Liu BC, Muendlein HI, Li P, Nilson R, Tang AY, Rongvaux A, Bunnell SC, Shao F, Green DR, Poltorak A (2018) Caspase-8 induces cleavage of gasdermin D to elicit pyroptosis during Yersinia infection. Proc Natl Acad Sci U S A 115:E10888-e10897PubMedPubMedCentralCrossRef
Sefik E, Qu R, Junqueira C, Kaffe E, Mirza H, Zhao J, Brewer JR, Han A, Steach HR, Israelow B, Blackburn HN, Velazquez SE, Chen YG, Halene S, Iwasaki A, Meffre E, Nussenzweig M, Lieberman J, Wilen CB, Kluger Y, Flavell RA (2022) Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature 606:585–593PubMedPubMedCentralCrossRef
Shi J, Zhao Y, Wang Y, Gao W, Ding J, Li P, Hu L, Shao F (2014) Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 514:187–192PubMedCrossRef
Shi CX, Wang Y, Chen Q, Jiao FZ, Pei MH, Gong ZJ (2020) Extracellular Histone H3 Induces Pyroptosis During Sepsis and May Act Through NOD2 and VSIG4/NLRP3 Pathways. Front Cell Infect Microbiol 10:196PubMedPubMedCentralCrossRef
Shimojima Y, Kishida D, Ueno KI, Ushiyama S, Ichikawa T, Sekijima Y (2019) Characteristics of Circulating Natural Killer Cells and Their Interferon-γ Production in Active Adult-onset Still Disease. J Rheumatol 46:1268–1276PubMedCrossRef
Shimojima Y, Ichikawa T, Kishida D, Takamatsu R, Sekijima Y (2021) Circulating regulatory T cells in adult-onset Still’s disease: Focusing on their plasticity and stability. Clin Exp Immunol 206:184–195PubMedPubMedCentralCrossRef
Solinas G, Marchesi F, Garlanda C, Mantovani A, Allavena P (2010) Inflammation-mediated promotion of invasion and metastasis. Cancer Metastasis Rev 29:243–248PubMedCrossRef
Sollberger G, Choidas A, Burn GL, Habenberger P, di Lucrezia R, Kordes S, Menninger S, Eickhoff J, Nussbaumer P, Klebl B, Krüger R, Herzig A, Zychlinsky A (2018) Gasdermin D plays a vital role in the generation of neutrophil extracellular traps. Sci Immunol 3:334CrossRef
Son S, Yoon SH, Chae BJ, Hwang I, Shim DW, Choe YH, Hyun YM, Yu JW (2021) Neutrophils facilitate prolonged inflammasome response in the DAMP-rich inflammatory milieu. Front Immunol 12:746032PubMedPubMedCentralCrossRef
Tan G, Huang C, Chen J, Chen B, Zhi F (2021a) Gasdermin-E-mediated pyroptosis participates in the pathogenesis of Crohn’s disease by promoting intestinal inflammation. Cell Rep 35:109265PubMedCrossRef
Tan Y, Sun R, Liu L, Yang D, Xiang Q, Li L, Tang J, Qiu Z, Peng W, Wang Y, Ye L, Ren G, Xiang T (2021b) Tumor suppressor DRD2 facilitates M1 macrophages and restricts NF-κB signaling to trigger pyroptosis in breast cancer. Theranostics 11:5214–5231PubMedPubMedCentralCrossRef
Thonhofer R, Hiller M, Just H, Trummer M, Siegel C, Dejaco C (2011) Treatment of refractory adult-onset Still’s disease with tocilizumab: report of two cases and review of the literature. Rheumatol Int 31:1653–1656PubMedCrossRef
Tsuboi H, Segawa S, Yagishita M, Toko H, Honda F, Kitada A, Miki H, Ohyama A, Hagiwara S, Kondo Y, Matsumoto I, Sumida T (2022) Activation mechanisms of monocytes/macrophages in adult-onset Still disease. Front Immunol 13:953730PubMedPubMedCentralCrossRef
Tufekci KU, Eltutan BI, Isci KB, Genc S (2021) Resveratrol Inhibits NLRP3 Inflammasome-Induced Pyroptosis and miR-155 Expression in Microglia Through Sirt1/AMPK Pathway. Neurotox Res 39:1812–1829PubMedCrossRef
Tupik JD, Markov Madanick JW, Ivester HM, Allen IC (2022) Detecting DNA: An Overview of DNA Recognition by Inflammasomes and Protection against Bacterial Respiratory Infections. Cells 11:1748CrossRef
Wang Y, Gao W, Shi X, Ding J, Liu W, He H, Wang K, Shao F (2017) Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature 547:99–103PubMedCrossRef
Wang Z, Chi H, Sun Y, Teng J, Feng T, Liu H, Cheng X, Ye J, Shi H, Hu Q, Jia J, Liu T, Wan L, Zhou Z, Qiao X, Yang C, Su Y (2020) Serum sTREM-1 in adult-onset Still’s disease: a novel biomarker of disease activity and a potential predictor of the chronic course. Rheumatology (oxford) 59:3293–3302PubMedCrossRef
Wang L, Chen Q, Yu Q, Xiao J, Zhao H (2021a) TREM-1 aggravates chronic obstructive pulmonary disease development via activation NLRP3 inflammasome-mediated pyroptosis. Inflamm Res 70:971–980PubMedCrossRef
Wang Y, Wang Y, Cai N, Xu T, He F (2021b) Anti-inflammatory effects of curcumin in acute lung injury: In vivo and in vitro experimental model studies. Int Immunopharmacol 96:107600PubMedCrossRef
Wang X, Wu T, Ma H, Huang X, Huang K, Ye C, Zhu S (2022a) VX-765 ameliorates inflammation and extracellular matrix accumulation by inhibiting the NOX1/ROS/NF-κB pathway in diabetic nephropathy. J Pharm Pharmacol 74:377–386PubMedCrossRef
Wang Y, Liu F, Liu M, Zhou X, Wang M, Cao K, Jin S, Shan A, Feng X (2022b) Curcumin mitigates aflatoxin B1-induced liver injury via regulating the NLRP3 inflammasome and Nrf2 signaling pathway. Food Chem Toxicol 161:112823PubMedCrossRef
Weber P, Wang P, Maddens S, Wang P, Wu R, Miksa M, Dong W, Mortimore M, Golec JM, Charlton P (2009) VX-166: a novel potent small molecule caspase inhibitor as a potential therapy for sepsis. Crit Care 13:R146PubMedPubMedCentralCrossRef
Wellenstein MD, Coffelt SB, Duits DEM, van Miltenburg MH, Slagter M, de Rink I, Henneman L, Kas SM, Prekovic S, Hau CS, Vrijland K, Drenth AP, De Korte-Grimmerink R, Schut E, van der Heijden I, Zwart W, Wessels LFA, Schumacher TN, Jonkers J, de Visser KE (2019) Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature 572:538–542PubMedPubMedCentralCrossRef
Wree A, Eguchi A, McGeough MD, Pena CA, Johnson CD, Canbay A, Hoffman HM, Feldstein AE (2014) NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology 59:898–910PubMedCrossRef
Wu XY, Li KT, Yang HX, Yang B, Lu X, Zhao LD, Fei YY, Chen H, Wang L, Li J, Peng LY, Zheng WJ, Hou Y, Jiang Y, Shi Q, Zhang W, Zhang FC, Zhang JM, Huang B, He W, Zhang X (2020) Complement C1q synergizes with PTX3 in promoting NLRP3 inflammasome over-activation and pyroptosis in rheumatoid arthritis. J Autoimmun 106:102336PubMedCrossRef
Wu J, Zhang J, Zhao J, Chen S, Zhou T, Xu J (2021) Treatment of Severe Acute Pancreatitis and Related Lung Injury by Targeting Gasdermin D-Mediated Pyroptosis. Front Cell Dev Biol 9:780142PubMedPubMedCentralCrossRef
Xu J, Jiang Y, Wang J, Shi X, Liu Q, Liu Z, Li Y, Scott MJ, Xiao G, Li S, Fan L, Billiar TR, Wilson MA, Fan J (2014) Macrophage endocytosis of high-mobility group box 1 triggers pyroptosis. Cell Death Differ 21:1229–1239PubMedPubMedCentralCrossRef
Xu YJ, Zheng L, Hu YW, Wang Q (2018) Pyroptosis and its relationship to atherosclerosis. Clin Chim Acta 476:28–37PubMedCrossRef
Xu P, Hong Y, Xie Y, Yuan K, Li J, Sun R, Zhang X, Shi X, Li R, Wu J, Liu X, Hu W, Sun W (2021) TREM-1 exacerbates neuroinflammatory injury via NLRP3 inflammasome-mediated pyroptosis in experimental subarachnoid hemorrhage. Transl Stroke Res 12:643–659PubMedCrossRef
Yan M, Li L, Wang Q, Shao X, Luo Q, Liu S, Li Y, Wang D, Zhang Y, Diao H, Rong X, Guo J (2022) The Chinese herbal medicine Fufang Zhenzhu Tiaozhi protects against diabetic cardiomyopathy by alleviating cardiac lipotoxicity-induced oxidative stress and NLRP3-dependent inflammasome activation. Biomed Pharmacother 148:112709PubMedCrossRef
Yasuda K, Nakanishi K, Tsutsui H (2019) Interleukin-18 in Health and Disease. Int J Mol Sci 20:334CrossRef
Yi YS (2022) Regulatory roles of Caspase-11 non-canonical inflammasome in inflammatory liver diseases. Int J Mol Sci 23:334CrossRef
Zhang Y, Chen X, Gueydan C, Han J (2018) Plasma membrane changes during programmed cell deaths. Cell Res 28:9–21PubMedCrossRef
Zhang JY, Zhou B, Sun RY, Ai YL, Cheng K, Li FN, Wang BR, Liu FJ, Jiang ZH, Wang WJ, Zhou D, Chen HZ, Wu Q (2021) The metabolite α-KG induces GSDMC-dependent pyroptosis through death receptor 6-activated caspase-8. Cell Res 31:980–997PubMedPubMedCentralCrossRef
Zhao C, Gu Y, Zeng X, Wang J (2018) NLRP3 inflammasome regulates Th17 differentiation in rheumatoid arthritis. Clin Immunol 197:154–160PubMedCrossRef
Zhaolin Z, Guohua L, Shiyuan W, Zuo W (2019) Role of pyroptosis in cardiovascular disease. Cell Prolif 52:e12563PubMedCrossRef
Zheng Y, Zhang J, Zhao Y, Zhang Y, Zhang X, Guan J, Liu Y, Fu J (2021) Curcumin protects against cognitive impairments in a rat model of chronic cerebral hypoperfusion combined with diabetes mellitus by suppressing neuroinflammation, apoptosis, and pyroptosis. Int Immunopharmacol 93:107422PubMedCrossRef
Zhou Z, He H, Wang K, Shi X, Wang Y, Su Y, Wang Y, Li D, Liu W, Zhang Y, Shen L, Han W, Shen L, Ding J, Shao F (2020) Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science 368:445CrossRef
Metadata
Title
Pyroptosis: the potential eye of the storm in adult-onset Still’s disease
Authors
Xinglan He
Ruixuan You
Yaqian Shi
Zhuotong Zeng
Bingsi Tang
Jiangfan Yu
Yangfan Xiao
Rong Xiao
Publication date
10-07-2023
Publisher
Springer International Publishing
Published in
Inflammopharmacology / Issue 5/2023
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-023-01275-0

Other articles of this Issue 5/2023

Inflammopharmacology 5/2023 Go to the issue

Original Article

The effect of magnesium sulfate on gene expression and serum level of inflammatory cytokines in coronary artery disease patients

Review

The association between neutrophil-to-lymphocyte ratio and disease activity in rheumatoid arthritis

Original Article

Inhibition of CD4 + T cells by fanchinoline via miR506-3p/NFATc1 in Sjögren’s syndrome

Original Article

Zinc and L-carnitine combination with or without methotrexate prevents intestinal toxicity during arthritis treatment via Nrf2/Sirt1/Foxo3 pathways: an In vivo and molecular docking approach

Original Article

A novel chitosan-based doxepin nano-formulation for chemotherapy-induced oral mucositis: a randomized, double-blinded, placebo-controlled clinical trial

Review

Impact of curcumin on p38 MAPK: therapeutic implications